您当前的位置：
首页 >
文章列表页 >
Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab
更新时间：2026-02-10

    • Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab

    • “Clinical pharmacists participated in the diagnosis and treatment of irCAEs in patients with gallbladder cancer induced by valuximab, proposed drug discontinuation and adjustment recommendations, improved patient symptoms, and provided reference for clinical medication safety.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 1, Pages: 88-91(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.01.16    

      CLC： R979.1;R969.3

    • Received：10 September 2025，

      Revised：2025-12-16，

      Accepted：18 December 2025，

      Published：15 January 2026

    移动端阅览

  • JI Liulian,QIN Zhengbi,LIU Pengcheng,et al.Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab[J].ZHONGGUO YAOFANG,2026,37(01):88-91. DOI： 10.6039/j.issn.1001-0408.2026.01.16.

  •  
  •  

0

Views

13

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Efficacy and safety of immune checkpoint inhibitors versus routine second-line chemotherapy for advanced esophageal cancer ：a meta-analysis
Meta-analysis of the correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer
Meta-analysis of Non-immune Related Adverse Event s Caused by ICIs Alone or Combined with Routine Che- motherapy in the Treatment of Non-small Cell Lung Cancer
Case Analysis of 15 Cases of Immune-related Myocarditis Induced by Pembrolizumab
肿瘤免疫检查点抑制剂及其联合疗法的研究进展

Related Author

CAI Hongfu
LYU Peiyu
OUYANG Hua
GAN Shuirong
ZHANG Qingshu
HE Jiao
LIU Xiaobo
DAI Wei

Related Institution

No data
0